Browsing HMS Scholarly Articles by Keyword "antiplatelet therapy"
Now showing items 1-2 of 2
-
Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States
(Blackwell Publishing Ltd, 2015)Background: Vorapaxar is a protease‐activated receptor‐1 antagonist approved by the U.S. Food and Drug Administration (FDA) for the reduction of thrombotic cardiovascular (CV) events in patients with a history of myocardial ... -
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial
(Lippincott Williams & Wilkins, 2016)Background— The Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX trial demonstrated superiority of cangrelor in reducing ischemic events at 48 hours in patients ...